Data from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor Article Swipe
Magalie Dosset
,
Yann Godet
,
Charline Vauchy
,
Laurent Beziaud
,
Yu Chun Lone
,
Christine Sedlik
,
Christelle Liard
,
Émeline Levionnois
,
Bertrand Clerc
,
Federico Sandoval
,
Étienne Daguindau
,
Simon Wain‐Hobson
,
Éric Tartour
,
Pierre Langlade‐Demoyen
,
Christophe Borg
,
Olivier Adotévi
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.6520469
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.6520469
Purpose: To evaluate CD4+ helper functions and antitumor effect of promiscuous universal cancer peptides (UCP) derived from telomerase reverse transcriptase (TERT).Experimental Design: To evaluate the widespread immunogenicity of UCPs in humans, spontaneous T-cell responses against UCPs were measured in various types of cancers using T-cell proliferation and ELISPOT assays. The humanized HLA-DRB1*0101/HLA-A*0201 transgenic mice were used to study the CD4+ helper effects of UCPs on antitumor CTL responses. UCP-based antitumor therapeutic vaccine was evaluated using HLA-A*0201–positive B16 melanoma that express TERT.Results: The presence of a high number of UCP-specific CD4+ T cells was found in the blood of patients with various types of cancer. These UCP-specific T cells mainly produce IFN-γ and TNF-α. In HLA transgenic mice, UCP vaccinations induced high avidity CD4+ TH1 cells and activated dendritic cells that produced interleukin-12. UCP-based vaccination breaks self-tolerance against TERT and enhances primary and memory CTL responses. Furthermore, the use of UCP strongly improves the efficacy of therapeutic vaccination against established B16-HLA-A*0201 melanoma and promotes tumor infiltration by TERT-specific CD8+ T cells.Conclusions: Our results showed that UCP-based vaccinations strongly stimulate antitumor immune responses and could be used to design efficient immunotherapies in multiple types of cancers. Clin Cancer Res; 18(22); 6284–95. ©2012 AACR.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.c.6520469
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4361944248
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4361944248Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.c.6520469Digital Object Identifier
- Title
-
Data from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established TumorWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-03-31Full publication date if available
- Authors
-
Magalie Dosset, Yann Godet, Charline Vauchy, Laurent Beziaud, Yu Chun Lone, Christine Sedlik, Christelle Liard, Émeline Levionnois, Bertrand Clerc, Federico Sandoval, Étienne Daguindau, Simon Wain‐Hobson, Éric Tartour, Pierre Langlade‐Demoyen, Christophe Borg, Olivier AdotéviList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.c.6520469Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.c.6520469Direct OA link when available
- Concepts
-
Telomerase, ELISPOT, Immunogenicity, CTL*, Molecular biology, Immunology, Cancer research, Medicine, T cell, Biology, Antibody, CD8, Antigen, Immune system, Biochemistry, GeneTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4361944248 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.c.6520469 |
| ids.doi | https://doi.org/10.1158/1078-0432.c.6520469 |
| ids.openalex | https://openalex.org/W4361944248 |
| fwci | |
| type | preprint |
| title | Data from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10580 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9983999729156494 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2403 |
| topics[0].subfield.display_name | Immunology |
| topics[0].display_name | Immunotherapy and Immune Responses |
| topics[1].id | https://openalex.org/T12996 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.991100013256073 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1305 |
| topics[1].subfield.display_name | Biotechnology |
| topics[1].display_name | Cancer Research and Treatments |
| topics[2].id | https://openalex.org/T10613 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9732000231742859 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1311 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Virus-based gene therapy research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C94581717 |
| concepts[0].level | 3 |
| concepts[0].score | 0.5472558736801147 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q331839 |
| concepts[0].display_name | Telomerase |
| concepts[1].id | https://openalex.org/C2779053233 |
| concepts[1].level | 4 |
| concepts[1].score | 0.5180802345275879 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q731235 |
| concepts[1].display_name | ELISPOT |
| concepts[2].id | https://openalex.org/C2780868878 |
| concepts[2].level | 3 |
| concepts[2].score | 0.5072190761566162 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1660197 |
| concepts[2].display_name | Immunogenicity |
| concepts[3].id | https://openalex.org/C147969180 |
| concepts[3].level | 4 |
| concepts[3].score | 0.4490634799003601 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q5014579 |
| concepts[3].display_name | CTL* |
| concepts[4].id | https://openalex.org/C153911025 |
| concepts[4].level | 1 |
| concepts[4].score | 0.3850792348384857 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q7202 |
| concepts[4].display_name | Molecular biology |
| concepts[5].id | https://openalex.org/C203014093 |
| concepts[5].level | 1 |
| concepts[5].score | 0.38303059339523315 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[5].display_name | Immunology |
| concepts[6].id | https://openalex.org/C502942594 |
| concepts[6].level | 1 |
| concepts[6].score | 0.3620087802410126 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[6].display_name | Cancer research |
| concepts[7].id | https://openalex.org/C71924100 |
| concepts[7].level | 0 |
| concepts[7].score | 0.3528136610984802 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[7].display_name | Medicine |
| concepts[8].id | https://openalex.org/C2776090121 |
| concepts[8].level | 3 |
| concepts[8].score | 0.34548646211624146 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q193529 |
| concepts[8].display_name | T cell |
| concepts[9].id | https://openalex.org/C86803240 |
| concepts[9].level | 0 |
| concepts[9].score | 0.32542991638183594 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[9].display_name | Biology |
| concepts[10].id | https://openalex.org/C159654299 |
| concepts[10].level | 2 |
| concepts[10].score | 0.276697039604187 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[10].display_name | Antibody |
| concepts[11].id | https://openalex.org/C167672396 |
| concepts[11].level | 3 |
| concepts[11].score | 0.2561127245426178 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q417800 |
| concepts[11].display_name | CD8 |
| concepts[12].id | https://openalex.org/C147483822 |
| concepts[12].level | 2 |
| concepts[12].score | 0.22277376055717468 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q103537 |
| concepts[12].display_name | Antigen |
| concepts[13].id | https://openalex.org/C8891405 |
| concepts[13].level | 2 |
| concepts[13].score | 0.1916307806968689 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[13].display_name | Immune system |
| concepts[14].id | https://openalex.org/C55493867 |
| concepts[14].level | 1 |
| concepts[14].score | 0.09964671730995178 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[14].display_name | Biochemistry |
| concepts[15].id | https://openalex.org/C104317684 |
| concepts[15].level | 2 |
| concepts[15].score | 0.09298825263977051 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[15].display_name | Gene |
| keywords[0].id | https://openalex.org/keywords/telomerase |
| keywords[0].score | 0.5472558736801147 |
| keywords[0].display_name | Telomerase |
| keywords[1].id | https://openalex.org/keywords/elispot |
| keywords[1].score | 0.5180802345275879 |
| keywords[1].display_name | ELISPOT |
| keywords[2].id | https://openalex.org/keywords/immunogenicity |
| keywords[2].score | 0.5072190761566162 |
| keywords[2].display_name | Immunogenicity |
| keywords[3].id | https://openalex.org/keywords/ctl* |
| keywords[3].score | 0.4490634799003601 |
| keywords[3].display_name | CTL* |
| keywords[4].id | https://openalex.org/keywords/molecular-biology |
| keywords[4].score | 0.3850792348384857 |
| keywords[4].display_name | Molecular biology |
| keywords[5].id | https://openalex.org/keywords/immunology |
| keywords[5].score | 0.38303059339523315 |
| keywords[5].display_name | Immunology |
| keywords[6].id | https://openalex.org/keywords/cancer-research |
| keywords[6].score | 0.3620087802410126 |
| keywords[6].display_name | Cancer research |
| keywords[7].id | https://openalex.org/keywords/medicine |
| keywords[7].score | 0.3528136610984802 |
| keywords[7].display_name | Medicine |
| keywords[8].id | https://openalex.org/keywords/t-cell |
| keywords[8].score | 0.34548646211624146 |
| keywords[8].display_name | T cell |
| keywords[9].id | https://openalex.org/keywords/biology |
| keywords[9].score | 0.32542991638183594 |
| keywords[9].display_name | Biology |
| keywords[10].id | https://openalex.org/keywords/antibody |
| keywords[10].score | 0.276697039604187 |
| keywords[10].display_name | Antibody |
| keywords[11].id | https://openalex.org/keywords/cd8 |
| keywords[11].score | 0.2561127245426178 |
| keywords[11].display_name | CD8 |
| keywords[12].id | https://openalex.org/keywords/antigen |
| keywords[12].score | 0.22277376055717468 |
| keywords[12].display_name | Antigen |
| keywords[13].id | https://openalex.org/keywords/immune-system |
| keywords[13].score | 0.1916307806968689 |
| keywords[13].display_name | Immune system |
| keywords[14].id | https://openalex.org/keywords/biochemistry |
| keywords[14].score | 0.09964671730995178 |
| keywords[14].display_name | Biochemistry |
| keywords[15].id | https://openalex.org/keywords/gene |
| keywords[15].score | 0.09298825263977051 |
| keywords[15].display_name | Gene |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.c.6520469 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.c.6520469 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5043542292 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3531-4371 |
| authorships[0].author.display_name | Magalie Dosset |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Magalie Dosset |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5089208521 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4017-6070 |
| authorships[1].author.display_name | Yann Godet |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Yann Godet |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5036429066 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Charline Vauchy |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Charline Vauchy |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5075650598 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-8526-3261 |
| authorships[3].author.display_name | Laurent Beziaud |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Laurent Beziaud |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5063305158 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7417-4930 |
| authorships[4].author.display_name | Yu Chun Lone |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Yu Chun Lone |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5063854495 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-8502-0905 |
| authorships[5].author.display_name | Christine Sedlik |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Christine Sedlik |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5050371738 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Christelle Liard |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Christelle Liard |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5074735464 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Émeline Levionnois |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Emeline Levionnois |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5110967089 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Bertrand Clerc |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Bertrand Clerc |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5081251214 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Federico Sandoval |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Federico Sandoval |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5042424335 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-7375-5656 |
| authorships[10].author.display_name | Étienne Daguindau |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Etienne Daguindau |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5013201108 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-6406-3858 |
| authorships[11].author.display_name | Simon Wain‐Hobson |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Simon Wain-Hobson |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5018415934 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-7323-468X |
| authorships[12].author.display_name | Éric Tartour |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Eric Tartour |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5006417997 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Pierre Langlade‐Demoyen |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Pierre Langlade-Demoyen |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5022288769 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-6161-0169 |
| authorships[14].author.display_name | Christophe Borg |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Christophe Borg |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5060518732 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-7742-136X |
| authorships[15].author.display_name | Olivier Adotévi |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | Olivier Adotévi |
| authorships[15].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.c.6520469 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10580 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9983999729156494 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2403 |
| primary_topic.subfield.display_name | Immunology |
| primary_topic.display_name | Immunotherapy and Immune Responses |
| related_works | https://openalex.org/W38648996, https://openalex.org/W2403399378, https://openalex.org/W1549922507, https://openalex.org/W1605884721, https://openalex.org/W2020995651, https://openalex.org/W2043713674, https://openalex.org/W1995555192, https://openalex.org/W4241189537, https://openalex.org/W3150349444, https://openalex.org/W2050296416 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.c.6520469 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.6520469 |
| primary_location.id | doi:10.1158/1078-0432.c.6520469 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.6520469 |
| publication_date | 2023-03-31 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.T | 90, 106, 168 |
| abstract_inverted_index.a | 84 |
| abstract_inverted_index.In | 113 |
| abstract_inverted_index.To | 1, 22 |
| abstract_inverted_index.be | 183 |
| abstract_inverted_index.by | 165 |
| abstract_inverted_index.in | 29, 38, 94, 189 |
| abstract_inverted_index.of | 9, 27, 41, 62, 83, 87, 97, 102, 148, 154, 192 |
| abstract_inverted_index.on | 64 |
| abstract_inverted_index.to | 56, 185 |
| abstract_inverted_index.B16 | 76 |
| abstract_inverted_index.CTL | 66, 143 |
| abstract_inverted_index.HLA | 114 |
| abstract_inverted_index.Our | 170 |
| abstract_inverted_index.The | 49, 81 |
| abstract_inverted_index.UCP | 117, 149 |
| abstract_inverted_index.and | 6, 46, 111, 125, 138, 141, 161, 181 |
| abstract_inverted_index.the | 24, 58, 95, 146, 152 |
| abstract_inverted_index.use | 147 |
| abstract_inverted_index.was | 72, 92 |
| abstract_inverted_index.Res; | 196 |
| abstract_inverted_index.TERT | 137 |
| abstract_inverted_index.UCPs | 28, 35, 63 |
| abstract_inverted_index.from | 16 |
| abstract_inverted_index.high | 85, 120 |
| abstract_inverted_index.mice | 53 |
| abstract_inverted_index.that | 78, 129, 173 |
| abstract_inverted_index.used | 55, 184 |
| abstract_inverted_index.were | 36, 54 |
| abstract_inverted_index.with | 99 |
| abstract_inverted_index.(UCP) | 14 |
| abstract_inverted_index.These | 104 |
| abstract_inverted_index.blood | 96 |
| abstract_inverted_index.cells | 91, 107, 124, 128 |
| abstract_inverted_index.could | 182 |
| abstract_inverted_index.found | 93 |
| abstract_inverted_index.mice, | 116 |
| abstract_inverted_index.study | 57 |
| abstract_inverted_index.tumor | 163 |
| abstract_inverted_index.types | 40, 101, 191 |
| abstract_inverted_index.using | 43, 74 |
| abstract_inverted_index.Cancer | 195 |
| abstract_inverted_index.IFN-γ | 110 |
| abstract_inverted_index.T-cell | 32, 44 |
| abstract_inverted_index.breaks | 134 |
| abstract_inverted_index.cancer | 12 |
| abstract_inverted_index.design | 186 |
| abstract_inverted_index.effect | 8 |
| abstract_inverted_index.helper | 4, 60 |
| abstract_inverted_index.immune | 179 |
| abstract_inverted_index.mainly | 108 |
| abstract_inverted_index.memory | 142 |
| abstract_inverted_index.number | 86 |
| abstract_inverted_index.showed | 172 |
| abstract_inverted_index.©2012 | 199 |
| abstract_inverted_index.18(22); | 197 |
| abstract_inverted_index.ELISPOT | 47 |
| abstract_inverted_index.TNF-α. | 112 |
| abstract_inverted_index.against | 34, 136, 157 |
| abstract_inverted_index.assays. | 48 |
| abstract_inverted_index.avidity | 121 |
| abstract_inverted_index.cancer. | 103 |
| abstract_inverted_index.cancers | 42 |
| abstract_inverted_index.derived | 15 |
| abstract_inverted_index.effects | 61 |
| abstract_inverted_index.express | 79 |
| abstract_inverted_index.humans, | 30 |
| abstract_inverted_index.induced | 119 |
| abstract_inverted_index.primary | 140 |
| abstract_inverted_index.produce | 109 |
| abstract_inverted_index.results | 171 |
| abstract_inverted_index.reverse | 18 |
| abstract_inverted_index.vaccine | 71 |
| abstract_inverted_index.various | 39, 100 |
| abstract_inverted_index.cancers. | 193 |
| abstract_inverted_index.efficacy | 153 |
| abstract_inverted_index.enhances | 139 |
| abstract_inverted_index.evaluate | 2, 23 |
| abstract_inverted_index.improves | 151 |
| abstract_inverted_index.measured | 37 |
| abstract_inverted_index.melanoma | 77, 160 |
| abstract_inverted_index.multiple | 190 |
| abstract_inverted_index.patients | 98 |
| abstract_inverted_index.peptides | 13 |
| abstract_inverted_index.presence | 82 |
| abstract_inverted_index.produced | 130 |
| abstract_inverted_index.promotes | 162 |
| abstract_inverted_index.strongly | 150, 176 |
| abstract_inverted_index.UCP-based | 68, 132, 174 |
| abstract_inverted_index.activated | 126 |
| abstract_inverted_index.antitumor | 7, 65, 69, 178 |
| abstract_inverted_index.dendritic | 127 |
| abstract_inverted_index.efficient | 187 |
| abstract_inverted_index.evaluated | 73 |
| abstract_inverted_index.functions | 5 |
| abstract_inverted_index.humanized | 50 |
| abstract_inverted_index.responses | 33, 180 |
| abstract_inverted_index.stimulate | 177 |
| abstract_inverted_index.universal | 11 |
| abstract_inverted_index.6284–95. | 198 |
| abstract_inverted_index.responses. | 67, 144 |
| abstract_inverted_index.telomerase | 17 |
| abstract_inverted_index.transgenic | 52, 115 |
| abstract_inverted_index.widespread | 25 |
| abstract_inverted_index.established | 158 |
| abstract_inverted_index.promiscuous | 10 |
| abstract_inverted_index.spontaneous | 31 |
| abstract_inverted_index.therapeutic | 70, 155 |
| abstract_inverted_index.vaccination | 133, 156 |
| abstract_inverted_index.Furthermore, | 145 |
| abstract_inverted_index.UCP-specific | 88, 105 |
| abstract_inverted_index.infiltration | 164 |
| abstract_inverted_index.vaccinations | 118, 175 |
| abstract_inverted_index.<i>Clin | 194 |
| abstract_inverted_index.TERT-specific | 166 |
| abstract_inverted_index.proliferation | 45 |
| abstract_inverted_index.transcriptase | 19 |
| abstract_inverted_index.B16-HLA-A*0201 | 159 |
| abstract_inverted_index.immunogenicity | 26 |
| abstract_inverted_index.self-tolerance | 135 |
| abstract_inverted_index.immunotherapies | 188 |
| abstract_inverted_index.interleukin-12. | 131 |
| abstract_inverted_index.Design:</b> | 21 |
| abstract_inverted_index.HLA-A*0201–positive | 75 |
| abstract_inverted_index.HLA-DRB1*0101/HLA-A*0201 | 51 |
| abstract_inverted_index.T<sub>H</sub>1 | 123 |
| abstract_inverted_index.CD4<sup>+</sup> | 3, 59, 89, 122 |
| abstract_inverted_index.CD8<sup>+</sup> | 167 |
| abstract_inverted_index.AACR</i>.</p></div> | 200 |
| abstract_inverted_index.(TERT).</p><p><b>Experimental | 20 |
| abstract_inverted_index.TERT.</p><p><b>Results:</b> | 80 |
| abstract_inverted_index.<div>Abstract<p><b>Purpose:</b> | 0 |
| abstract_inverted_index.cells.</p><p><b>Conclusions:</b> | 169 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 16 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7900000214576721 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.13070465 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |